Search
Now showing items 1-1 of 1
Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
(2016-08-01)
An attractive molecular target for novel anti-cancer therapies is the
phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)
pathway which is commonly deregulated in many types of cancer. Nevertheless, ...